Week-by-week timeline
| Week | Dose | What to expect |
|---|---|---|
| Week 1-2 | 0.25mg | First nausea/GI side effects. Mild appetite suppression begins. |
| Week 3-4 | 0.25mg | Side effects subside. Reduced cravings noticeable. 0.5-1.5kg weight loss typical. |
| Week 5-8 | 0.5mg | Brief return of nausea after dose increase, then adaptation. Appetite suppression strengthens. 2-4kg total. |
| Week 9-12 | 0.5mg or 1.0mg | Steady-state therapeutic effect. 3-6kg total weight loss typical. Clothes fit differently. |
| Month 4-6 | Maintenance | 5-10% body weight loss. Visible body composition changes. Most patients report sustained energy + reduced food preoccupation. |
| Month 7-12 | Maintenance | 8-12% body weight loss typical. Rate slows but continues. Significant cardiovascular/metabolic improvements. |
| Month 12-18 | Maintenance | Approaching plateau. 10-15% total weight loss for typical responders. |
| Month 18+ | Maintenance | Plateau weight. Continued therapy maintains the loss. Lifestyle factors become more important. |
Why the first month feels slow (and why that’s intentional)
The first 4 weeks at 0.25mg weekly is the tolerability dose, it is deliberately sub-therapeutic for weight management. The point of this phase is to let your body adapt to the GLP-1 mechanism without overwhelming GI side effects. Patients who rush through escalation report dramatically worse nausea.
Real therapeutic effect starts at 0.5mg (week 5) and strengthens at 1.0mg (week 9-12). If you’re not losing weight in month 1, that is expected, judge the medication's effect at month 3-4 once you’ve been on maintenance dose for 6-8 weeks.
What "working" actually means (it’s not just weight)
The visible outcome is weight loss, but Ozempic's effects extend beyond the scale:
- Reduced food preoccupation. Patients consistently report the "food noise" quieting, fewer intrusive thoughts about meals, snacks, cravings. This is often the first noticeable change.
- Earlier satiety. Meals feel filling much sooner. Portion sizes naturally shrink.
- Reduced alcohol craving. Many patients report less desire to drink alcohol (an emerging area of research).
- Improved metabolic markers. HbA1c improvements (in diabetic patients), reduced fasting glucose, improved lipid profile, lower blood pressure, often visible at month 3-6 blood work.
- Cardiovascular benefit. Long-term trials (SUSTAIN-6, SELECT) showed reduced major adverse cardiovascular events with semaglutide use, particularly relevant for high-risk patients.
Are you a "non-responder"?
Approximately 5-10% of patients lose less than 5% body weight after 16 weeks at maximum tolerated dose. If you fit this pattern, options include:
- Continue and reassess. Sometimes the response takes longer to develop, particularly in patients with insulin resistance.
- Escalate to Wegovy. Higher dose (2.4mg) often unlocks response in patients capped at Ozempic 1.0mg.
- Switch to Mounjaro. Tirzepatide's dual mechanism produces response in some patients who don’t respond to pure GLP-1 agonists. See our Ozempic vs Mounjaro guide.
- Review diet/activity. GLP-1s reduce appetite but don’t override calorie intake. A registered dietitian review can identify hidden barriers.
- Investigate medical causes. Hypothyroidism, sleep apnoea, hormonal imbalances, depression, certain medications can all suppress weight loss response.
Plot your realistic projection
Our BMI + weight loss projection calculator models likely 12-month outcomes based on your starting BMI, age, and chosen medication. It uses STEP trial averages with confidence intervals, not the marketing best-case numbers.